| Identification | Back Directory | [Name]
Benz[a]indolo[2,3-g]quinolizine-9(6H)-methanol, 5,8,14,14a-tetrahydro-2,12-dimethoxy-3-(phenylmethoxy)- | [CAS]
2135765-21-6 | [Synonyms]
DC371739
Benz[a]indolo[2,3-g]quinolizine-9(6H)-methanol, 5,8,14,14a-tetrahydro-2,12-dimethoxy-3-(phenylmethoxy)- | [Molecular Formula]
C29H30N2O4 | [MOL File]
2135765-21-6.mol | [Molecular Weight]
470.56 |
| Chemical Properties | Back Directory | [Boiling point ]
654.2±55.0 °C(Predicted) | [density ]
1.29±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
14.30±0.10(Predicted) | [color ]
Light yellow to light brown |
| Hazard Information | Back Directory | [Uses]
DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia[1][2]. | [in vivo]
DC371739 (10, 30, 100 mg/kg; p.o.; daily for 21 days) decreases the plasma levels of total cholesterol (TC), LDL-cholesterol (LDL-C) and triglyceride in hamsters[2]. | Animal Model: | Six-week-old healthy male Syrian golden hamsters (HFD-fed) [2] | | Dosage: | 10, 30, 100 mg/kg | | Administration: | P.o.; daily for 21 days | | Result: | Decreased the serum TC levels of the hamsters treated with 10, 30, or 100 mg/kg by 29.46%, 35.65%, and 38.69%, the serum LDL-C levels were significantly lower by 23.25%, 31.04%, and 35.03%, respectively, led to significantly lower serum TG levels by 49.57%, 57.52%, and 78.16%. |
| [References]
[1] Bao X, et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024 Jan 8;9(1):13. DOI:10.1038/s41392-023-01690-3
[2] Wang J, et al. Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial. Cell Metab. 2022 May 3;34(5):667-680.e6. DOI:10.1016/j.cmet.2022.03.006 |
|
|